The Exciting Potential of Trispecific Antibodies in Myeloma

44 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this installment of Chief Insights in Oncology, John Burke, MD, of Rocky Mountain Cancer Centers in Denver, Colorado, and co-physician editor in chief, highlighted the exciting new results for a novel trispecific antibody called JNJ-5322, presented at recent summer meetings. This therapy is considered a trispecific antibody because it targets 3 different markers: CD3 on T cells and both BCMA and GPRC5D on plasma cells, essentially combining the targets of 2 different bispecific antibodies.

Read Dr Burke's column from the September I 2025 issue of Targeted Therapies in Oncology: https://www.targetedonc.com/view/impressive-results-of-trispecific-antibody-in-myeloma-presented-at-eha-2025-congress
Categoria
Oncology
Commenta per primo questo video.

Prossimo